Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 955

1.

Prognostic Significance of Nucleolar Assessment in Invasive Breast Cancer.

Elsharawy KA, Toss MS, Abuelmaaty SR, Ball G, Green AR, Aleskandarany MA, Dalton LW, Rakha EA.

Histopathology. 2019 Nov 17. doi: 10.1111/his.14036. [Epub ahead of print]

PMID:
31736094
2.

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

Kurozumi S, Alsaeed S, Orah N, Miligy IM, Joseph C, Aljohani A, Toss MS, Fujii T, Shirabe K, Green AR, Aleskandarany MA, Rakha EA.

Breast Cancer Res Treat. 2019 Nov 9. doi: 10.1007/s10549-019-05488-2. [Epub ahead of print]

PMID:
31707510
3.

How Clinicians Discuss Medications During Primary Care Encounters Among Older Adults with Cognitive Impairment.

Green AR, Wolff JL, Echavarria DM, Chapman M, Phung A, Smith D, Boyd CM.

J Gen Intern Med. 2019 Nov 8. doi: 10.1007/s11606-019-05424-6. [Epub ahead of print]

PMID:
31705465
4.

Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer.

Kariri YA, Joseph C, Kurozumi S, Toss MS, Alsaleem M, Raafat S, Mongan NP, Aleskandarany MA, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Nov 2. doi: 10.1007/s10549-019-05466-8. [Epub ahead of print]

PMID:
31679074
5.

How Can We Optimize Care and Outcomes for Patients with Mild Cognitive Impairment and Acute Myocardial Infarction?

Green AR.

J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05484-8. [Epub ahead of print] No abstract available.

PMID:
31659666
6.

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Aljohani AI, Toss MS, Kurozumi S, Joseph C, Aleskandarany MA, Miligy IM, Ansari RE, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Oct 10. doi: 10.1007/s10549-019-05459-7. [Epub ahead of print]

PMID:
31599393
7.

The Role of Glutaminase in Cancer.

Masisi BK, El Ansari R, Alfarsi L, Rakha EA, Green AR, Craze ML.

Histopathology. 2019 Oct 9. doi: 10.1111/his.14014. [Epub ahead of print] Review.

PMID:
31596504
8.

Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Joseph C, Al-Izzi S, Alsaleem M, Kurozumi S, Toss MS, Arshad M, Goh FQ, Alshankyty IM, Aleskandarany MA, Ali S, Ellis IO, Mongan NP, Green AR, Rakha EA.

Br J Cancer. 2019 Oct;121(9):776-785. doi: 10.1038/s41416-019-0589-0. Epub 2019 Sep 27.

PMID:
31558802
9.

The intra-tumoural stroma in patients with breast cancer increases with age.

Vangangelt KMH, Kramer CJH, Bastiaannet E, Putter H, Cohen D, van Pelt GW, Rakha EA, Green AR, Tollenaar RAEM, Mesker WE.

Breast Cancer Res Treat. 2019 Sep 18. doi: 10.1007/s10549-019-05422-6. [Epub ahead of print]

PMID:
31535319
10.

Cohesin-dependent regulation of gene expression during differentiation is lost in Cohesin-mutated myeloid malignancies.

Sasca D, Yun H, Giotopoulos G, Szybinski J, Evan T, Wilson NK, Gerstung M, Gallipoli P, Green AR, Hills RK, Russell NH, Osborne CS, Papaemmanuil E, Gottgens B, Campbell PJ, Huntly BJP.

Blood. 2019 Sep 12. pii: blood.2019001553. doi: 10.1182/blood.2019001553. [Epub ahead of print]

PMID:
31515253
11.

Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer.

Ziliotto S, Gee JMW, Ellis IO, Green AR, Finlay P, Gobbato A, Taylor KM.

Metallomics. 2019 Sep 1;11(9):1579-1592. doi: 10.1039/c9mt00136k. Epub 2019 Sep 4.

12.

CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.

Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Dec;178(3):535-544. doi: 10.1007/s10549-019-05420-8. Epub 2019 Aug 30.

PMID:
31471836
13.

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.

Abdel-Fatah TMA, Ali R, Sadiq M, Moseley PM, Mesquita KA, Ball G, Green AR, Rakha EA, Chan SYT, Madhusudan S.

Cancers (Basel). 2019 Aug 10;11(8). pii: E1149. doi: 10.3390/cancers11081149.

14.

Machine learning-based prediction of breast cancer growth rate in vivo.

Bhattarai S, Klimov S, Aleskandarany MA, Burrell H, Wormall A, Green AR, Rida P, Ellis IO, Osan RM, Rakha EA, Aneja R.

Br J Cancer. 2019 Sep;121(6):497-504. doi: 10.1038/s41416-019-0539-x. Epub 2019 Aug 9.

PMID:
31395950
15.

Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.

Bhattarai S, Klimov S, Mittal K, Krishnamurti U, Li XB, Oprea-Ilies G, Wetherilt CS, Riaz A, Aleskandarany MA, Green AR, Ellis IO, Cantuaria G, Gupta M, Manne U, Agboola J, Baskovich B, Janssen EAM, Callagy G, Walsh EM, Mehta A, Dogra A, Shet T, Gajaria P, Traina T, Nggada HA, Omonisi A, Ahmed SA, Rakha EA, Rida P, Aneja R.

Cancers (Basel). 2019 Jul 17;11(7). pii: E995. doi: 10.3390/cancers11070995.

16.

Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution.

Miligy IM, Toss MS, Khout H, Whisker L, Burrell HC, Ellis IO, Green AR, Macmillan D, Rakha EA.

Breast J. 2019 Nov;25(6):1143-1153. doi: 10.1111/tbj.13425. Epub 2019 Jul 18.

PMID:
31318120
17.

Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles.

Agrawal U, Soria D, Wagner C, Garibaldi J, Ellis IO, Bartlett JMS, Cameron D, Rakha EA, Green AR.

Artif Intell Med. 2019 Jun;97:27-37. doi: 10.1016/j.artmed.2019.05.002. Epub 2019 May 15.

PMID:
31202397
18.

Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, Aleskandarany MA, Alkawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1460-1472. doi: 10.1038/s41379-019-0286-9. Epub 2019 Jun 7.

PMID:
31175327
19.

Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Mittal K, Aneja R, Ellis IO, Green AR, Roxanis I, Rakha EA.

Mod Pathol. 2019 Oct;32(10):1473-1485. doi: 10.1038/s41379-019-0296-7. Epub 2019 Jun 7.

PMID:
31175326
20.
21.

A key genomic subtype associated with lymphovascular invasion in invasive breast cancer.

Kurozumi S, Joseph C, Sonbul S, Alsaeed S, Kariri Y, Aljohani A, Raafat S, Alsaleem M, Ogden A, Johnston SJ, Aleskandarany MA, Fujii T, Shirabe K, Caldas C, Ashankyty I, Dalton L, Ellis IO, Desmedt C, Green AR, Mongan NP, Rakha EA.

Br J Cancer. 2019 Jun;120(12):1129-1136. doi: 10.1038/s41416-019-0486-6. Epub 2019 May 22.

PMID:
31114020
22.

Clinicians' Perspectives on Barriers and Enablers of Optimal Prescribing in Patients with Dementia and Coexisting Conditions.

Green AR, Lee P, Reeve E, Wolff JL, Chen CCG, Kruzan R, Boyd CM.

J Am Board Fam Med. 2019 May-Jun;32(3):383-391. doi: 10.3122/jabfm.2019.03.180335.

23.

Investigation of the Amide Proton Solvent Exchange Properties of Glycosaminoglycan Oligosaccharides.

Green AR, Li K, Lockard B, Young RP, Mueller LJ, Larive CK.

J Phys Chem B. 2019 Jun 6;123(22):4653-4662. doi: 10.1021/acs.jpcb.9b01794. Epub 2019 May 22.

24.

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.

Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2019 May;120(11):1075-1082. doi: 10.1038/s41416-019-0436-3. Epub 2019 May 8.

PMID:
31065110
25.

Notch Signaling Mediates Secondary Senescence.

Teo YV, Rattanavirotkul N, Olova N, Salzano A, Quintanilla A, Tarrats N, Kiourtis C, Müller M, Green AR, Adams PD, Acosta JC, Bird TG, Kirschner K, Neretti N, Chandra T.

Cell Rep. 2019 Apr 23;27(4):997-1007.e5. doi: 10.1016/j.celrep.2019.03.104.

26.

Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer.

Kurozumi S, Joseph C, Raafat S, Sonbul S, Kariri Y, Alsaeed S, Pigera M, Alsaleem M, Nolan CC, Johnston SJ, Aleskandarany MA, Ogden A, Fujii T, Shirabe K, Martin SG, Alshankyty I, Mongan NP, Ellis IO, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Jul;176(1):63-73. doi: 10.1007/s10549-019-05216-w. Epub 2019 Apr 2.

PMID:
30941650
27.

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.

Rueda OM, Sammut SJ, Seoane JA, Chin SF, Caswell-Jin JL, Callari M, Batra R, Pereira B, Bruna A, Ali HR, Provenzano E, Liu B, Parisien M, Gillett C, McKinney S, Green AR, Murphy L, Purushotham A, Ellis IO, Pharoah PD, Rueda C, Aparicio S, Caldas C, Curtis C.

Nature. 2019 Mar;567(7748):399-404. doi: 10.1038/s41586-019-1007-8. Epub 2019 Mar 13.

28.

Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma.

Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, Doyle M, Semple T, Sufyan W, Byrne DJ, Pang JB, Murugasu A, Miligy IM, Green AR, Rakha EA, Fox SB, Mann GB, Campbell IG, Gorringe KL.

J Pathol. 2019 Jul;248(3):326-338. doi: 10.1002/path.5262. Epub 2019 Apr 22.

PMID:
30843206
29.

SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.

Abdel-Fatah TMA, Broom RJ, Lu J, Moseley PM, Huang B, Li L, Liu S, Chen L, Ma RZ, Cao W, Wang X, Li Y, Perry JK, Aleskandarany M, Nolan CC, Rakha EA, Lobie PE, Chan SYT, Ellis IO, Hwang LA, Lane DP, Green AR, Liu DX.

Br J Cancer. 2019 Apr;120(7):728-745. doi: 10.1038/s41416-019-0405-x. Epub 2019 Feb 28.

PMID:
30816325
30.

1H NMR characterization of chitin tetrasaccharide in binary H2O:DMSO solution: Evidence for anomeric end-effect propagation.

Li K, Green AR, Dinges MM, Larive CK.

Int J Biol Macromol. 2019 May 15;129:744-749. doi: 10.1016/j.ijbiomac.2019.02.062. Epub 2019 Feb 13.

PMID:
30771389
31.

The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts.

Alsaleem M, Toss MS, Joseph C, Aleskandarany M, Kurozumi S, Alshankyty I, Ogden A, Rida PCG, Ellis IO, Aneja R, Green AR, Mongan NP, Rakha EA.

Mod Pathol. 2019 Jul;32(7):967-976. doi: 10.1038/s41379-019-0209-9. Epub 2019 Feb 13.

PMID:
30760857
32.
33.

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.

Savva C, De Souza K, Ali R, Rakha EA, Green AR, Madhusudan S.

Breast Cancer Res Treat. 2019 May;175(1):105-115. doi: 10.1007/s10549-018-05113-8. Epub 2019 Feb 12.

34.

Clonal approaches to understanding the impact of mutations on hematologic disease development.

Nangalia J, Mitchell E, Green AR.

Blood. 2019 Mar 28;133(13):1436-1445. doi: 10.1182/blood-2018-11-835405. Epub 2019 Feb 6. Review.

PMID:
30728143
35.

The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, Ellis IO, Green AR, Rakha EA.

Histopathology. 2019 Jun;74(7):1025-1035. doi: 10.1111/his.13835. Epub 2019 Apr 14.

PMID:
30725481
36.

Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.

Syed BM, Green AR, Morgan DAL, Ellis IO, Cheung KL.

Cancers (Basel). 2019 Jan 28;11(2). pii: E149. doi: 10.3390/cancers11020149.

37.

The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.

El-Ansari R, Craze ML, Alfarsi L, Soria D, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 May;175(1):27-38. doi: 10.1007/s10549-018-05111-w. Epub 2019 Jan 22.

PMID:
30671766
38.

Caring for Patients With Multiple Chronic Conditions.

Tinetti ME, Green AR, Ouellet J, Rich MW, Boyd C.

Ann Intern Med. 2019 Feb 5;170(3):199-200. doi: 10.7326/M18-3269. Epub 2019 Jan 22. No abstract available. Erratum in: Ann Intern Med. 2019 Mar 5;170(5):356.

PMID:
30665237
39.

Decision Making for Older Adults With Multiple Chronic Conditions: Executive Summary for the American Geriatrics Society Guiding Principles on the Care of Older Adults With Multimorbidity.

Boyd C, Smith CD, Masoudi FA, Blaum CS, Dodson JA, Green AR, Kelley A, Matlock D, Ouellet J, Rich MW, Schoenborn NL, Tinetti ME.

J Am Geriatr Soc. 2019 Apr;67(4):665-673. doi: 10.1111/jgs.15809. Epub 2019 Mar 10.

PMID:
30663782
40.
41.

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Alhudiri IM, Nolan CC, Ellis IO, Elzagheid A, Rakha EA, Green AR, Chapman CJ.

Breast Cancer Res Treat. 2019 Apr;174(3):661-668. doi: 10.1007/s10549-018-05092-w. Epub 2019 Jan 4.

PMID:
30610489
42.

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.

Joseph C, Arshad M, Kurozomi S, Althobiti M, Miligy IM, Al-Izzi S, Toss MS, Goh FQ, Johnston SJ, Martin SG, Ellis IO, Mongan NP, Green AR, Rakha EA.

Breast Cancer Res Treat. 2019 Apr;174(2):387-399. doi: 10.1007/s10549-018-05085-9. Epub 2018 Dec 15.

PMID:
30554343
43.

Connexin 43 is an independent predictor of patient outcome in breast cancer patients.

Chasampalioti M, Green AR, Ellis IO, Rakha EA, Jackson AM, Spendlove I, Ramage JM.

Breast Cancer Res Treat. 2019 Feb;174(1):93-102. doi: 10.1007/s10549-018-5063-9. Epub 2018 Nov 24.

44.

Glutamate dehydrogenase (GLUD1) expression in breast cancer.

Craze ML, El-Ansari R, Aleskandarany MA, Cheng KW, Alfarsi L, Masisi B, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Feb;174(1):79-91. doi: 10.1007/s10549-018-5060-z. Epub 2018 Nov 23.

PMID:
30470977
45.

Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.

Toss MS, Miligy IM, Gorringe KL, McCaffrey L, AlKawaz A, Abidi A, Ellis IO, Green AR, Rakha EA.

Mod Pathol. 2019 May;32(5):639-649. doi: 10.1038/s41379-018-0180-x. Epub 2018 Nov 14.

PMID:
30429518
46.

Prolyl-4-hydroxylase Α subunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS).

Toss MS, Miligy IM, Gorringe KL, AlKawaz A, Khout H, Ellis IO, Green AR, Rakha EA.

Br J Cancer. 2018 Dec;119(12):1518-1526. doi: 10.1038/s41416-018-0337-x. Epub 2018 Nov 9.

47.

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Green AR, Freedman C, Tena J, Tourdot BE, Liu B, Holinstat M, Holman TR.

Biochemistry. 2018 Dec 4;57(48):6726-6734. doi: 10.1021/acs.biochem.8b00889. Epub 2018 Nov 15.

PMID:
30407793
48.

Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.

Johnston SJ, Ahmad D, Aleskandarany MA, Kurozumi S, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA.

BMC Cancer. 2018 Oct 23;18(1):1027. doi: 10.1186/s12885-018-4924-2.

49.

Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.

Alfarsi LH, Elansari R, Toss MS, Diez-Rodriguez M, Nolan CC, Ellis IO, Rakha EA, Green AR.

Breast Cancer Res Treat. 2019 Jan;173(1):93-102. doi: 10.1007/s10549-018-4978-5. Epub 2018 Oct 10.

PMID:
30306428
50.

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.

Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ.

N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.

Supplemental Content

Loading ...
Support Center